Clinical Trials Logo

Clinical Trial Summary

The aim of this observational case-control study was to investigate the effect of diabetic peripheral neuropathy symptoms on temporomandibular joint functionality in patients with type 2 diabetes.


Clinical Trial Description

The number of participants planned to be included in the study was decided with the G-Power programme. While calculating the number of individuals to be included in the study, it was calculated that the sample size to obtain an effect size of 0.6 for the purpose of evaluation within the 95% confidence interval in a way to provide 80% study power at 5% Type 1 and 20% Type 2 error limits should be 74 (n=37) individuals. This study included 70 individuals (DM study group=40 individuals, control group=30 individuals). Peripheral neuropathy symptoms of all participants were evaluated with the Michigan Neuropathy Screening Test. In the evaluation of TMJ functionality, the presence of pain, maximum pain-free mouth opening, mandibular dysfunction and dysfunction were assessed with the help of scales. Duration of diabetes mellitus was recorded and quality of life was evaluated with Ferran Powers Quality of Life Index. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06188572
Study type Observational
Source Bandirma Onyedi Eylül University
Contact
Status Completed
Phase
Start date May 1, 2023
Completion date November 15, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04940962 - Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion N/A
Completed NCT05359341 - Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients? N/A
Recruiting NCT04700813 - Research Study for Rare Pathogenic Mutations Causing Type 2 Diabetes and Complications
Completed NCT05413330 - Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes. Phase 2/Phase 3
Recruiting NCT04927377 - Accessible and Inclusive Diabetes Telecoaching Self-Management Program N/A
Completed NCT05585268 - Electronic Decision Support for Deprescribing in Patients on Hemodialysis N/A
Active, not recruiting NCT05088616 - Native American Diabetes Project N/A
Not yet recruiting NCT03273738 - Vascular and Metabolic Changes in Postmenopausal Diabetics
Active, not recruiting NCT04642911 - Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy
Withdrawn NCT04283617 - Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study N/A
Recruiting NCT04769687 - Symbiotics and Systemic Inflammation in Chronic Kidney Disease Phase 2
Withdrawn NCT06104358 - Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes Phase 2
Recruiting NCT03341793 - Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery N/A
Not yet recruiting NCT06080802 - The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction Phase 2/Phase 3
Recruiting NCT04485845 - Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression Phase 4
Recruiting NCT05050500 - The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction Phase 4
Completed NCT04115657 - The Effect of Different Starches of Boba Pearls and Sugar Substitutes Used in Milk Tea on Glycaemia, Insulinaemia and Appetite Control (Pearl Study) N/A
Completed NCT04120844 - Effectiveness of Motivational Interviewing on Improving Care for Type 2 Diabetes Mellitus Patients in China N/A
Completed NCT05789706 - Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans N/A
Recruiting NCT05776420 - Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes Phase 3